Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
22 Agosto 2022 - 3:05PM
Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today
announced that the United States Patent and Trademark Office
(USPTO) has issued a Notice of Allowance for Opiant’s pipeline
candidate OPNT004 (drinabant) for the treatment of cannabinoid
hyperemesis syndrome (CHS), a condition among cannabis users that
leads to repeated and severe bouts of vomiting. A Notice of
Allowance is issued after the USPTO decides that a patent can be
granted from an application.
"This patent allowance is welcome news, and a testament to our
commitment of bringing innovative science to the treatment of
addictions and drug overdose,” said Roger Crystal, M.D., President
and Chief Executive Officer of Opiant. “With the consumption of
cannabis increasing, due in large part to the legalization of its
recreational use, we are developing OPNT004 in anticipation that
emergency departments may receive more and more cases of side
effects related to chronic or heavy use.1 Drinabant is being
developed as an injection, which is ideal for these patients, who
have frequent bouts of intractable nausea and vomiting that are
generally unresponsive to traditional anti-emetics.”
The USPTO issued a Notice of Allowance for U.S. Patent
Application 16/904,359, entitled “Compositions and methods for
treating cannabinoid hyperemesis syndrome with a cannabinoid
receptor antagonist” for OPNT004. This patent covers OPNT004 as a
method of treatment for CHS using drinabant administered as a
parenteral formulation. Opiant expects this patent to issue
within the next few months and expire no earlier
than 2040.
About OPNT004OPNT004 (drinabant) is a high
affinity, CB-1 antagonist for the treatment of excessive
cannabinoid use. Cannabinoids are compounds found in the cannabis
plant or made synthetically, that bind to cannabinoid receptors
found in the central nervous system, gastrointestinal tract and
immune system. With support from the National Center for Advancing
Translational Sciences (NCATS), Opiant is developing a
formulation for the parenteral administration of OPNT004 for the
potential treatment of cannabinoid-related toxicities, which
include cannabinoid hyperemesis syndrome (CHS) and acute
cannabinoid overdose (ACO), a condition when excessive
tetrahydrocannabinol (THC) can cause anxiety, paranoia, visual and
auditory hallucinations, and nausea. There are currently no FDA
approved therapeutics for either CHS or ACO. Opiant expects to
initiate Phase I studies for OPNT004 in 2023. Opiant is developing
drinabant under a license from Sanofi-Aventis.
About cannabis hyperemesis syndrome
(CHS)Cannabinoid hyperemesis syndrome (CHS) is a syndrome
of cyclic vomiting associated with cannabis use. While the onset of
symptoms is sudden, CHS occurs in people who use cannabis
regularly, and has been linked to long term cannabis use. People
with CHS experience reoccurring episodes of nausea, vomiting,
dehydration, and abdominal pain, which can result in frequent
visits to the emergency department. The condition is generally
unresponsive to traditional anti-emetics, which are medications
used to prevent or treat nausea and vomiting. However, CHS can lead
to health complications if left untreated. Only a small portion of
people who regularly use cannabis develop CHS. Because CHS was
first described in the medical literature less than 20 years ago,
many people may have it and either not report it or are
misdiagnosed. One analysis found that CHS was responsible for up to
6% of patients who visited the emergency room for vomiting.2
About Opiant Pharmaceuticals,
Inc. Opiant Pharmaceuticals, Inc., the company that
developed NARCAN® Nasal Spray, is building a
leading franchise of new medicines to combat addictions
and drug overdose. For more information
visit: www.opiant.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance, or
achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied
or inferred by these forward-looking statements, and among other
things, the completion of the development of OPNT004. In some
cases, you can identify forward-looking statements by terminology
such as "may," "will," "should," "could," "would," "expects,"
"plans," "intends," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," or "continue" or the negative
of such terms and other comparable terminology. These statements
are only predictions based on our current expectations and
projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. In evaluating these statements, you should specifically
consider various factors. Additional factors that could materially
affect actual results can be found in our Form 10-K for the year
ended December 31, 2021, and our Form 10-Q for the quarter
ended June 30, 2022, filed with the Securities and Exchange
Commission on March 4, 2022, and August 11, 2022,
respectively, including under the caption titled "Risk Factors."
These and other factors may cause our actual results to
differ materially from any forward-looking statement. We undertake
no obligation to update any of the forward-looking statements after
the date of this press release to conform those statements to
reflect the occurrence of unanticipated events, except as required
by applicable law.
For Media and Investor Inquiries:Ben Atkins, Opiant(310)
598-5410batkins@opiant.com
- The United Nations World Drug Report 2022; Press Release:
https://www.unodc.org/unodc/en/frontpage/2022/June/unodc-world-drug-report-2022-highlights-trends-on-cannabis-post-legalization--environmental-impacts-of-illicit-drugs--and-drug-use-among-women-and-youth.html
- Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid
hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012
Feb;87(2):114-9. doi: 10.1016/j.mayocp.2011.10.005. PMID: 22305024;
PMCID: PMC3538402.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Gráfica de Acción Histórica
De May 2023 a May 2024